BRIC-Translational Health Science and Technology Institute (THSTI) is an Institute of the Biotechnology Research and Innovation Council, Department of Biotechnology, Ministry of Science & Technology, Govt. of India. The institute conducts innovative translational research and to develop research collaborations across disciplines and professions to translate concepts into products to improve human health.

This recruitment is to fill up the vacancies of BRIC-THSTI under the following projects:

Pfizer is the world's premier biopharmaceutical company taking new approaches to better health.  We discover, develop, manufacture and deliver quality, safe and effective prescription medicines to treat and help prevent disease for both people and animals. We also partner with healthcare providers, governments and local communities around the world to expand access to our medicines and to provide better quality health care and health system support.

Post : Executive Production

EMBO Postdoctoral Fellowships support excellent postdoctoral researchers throughout Europe and the world for a period of up to two years. International mobility is a key requirement. The fellowship includes a salary or stipend, a relocation allowance and support for fellows with children. Awardees can attend an EMBO Laboratory Leadership course and become part of the global network of EMBO Fellows.  

Postdoctoral Fellowships

Objective of Postdoctoral Fellowships
The objective of PFs is to support researchers’ careers and foster excellence in research. The Postdoctoral Fellowships action targets researchers holding a PhD who wish to carry out their research activities abroad, acquire new skills and develop their careers. PFs help researchers gain experience in other countries, disciplines and non-academic sectors.

Post : Postdoctoral Fellowships

Johnson & Johnson (J&J) has announced a proposed 5.5 billion USD settlement aimed at resolving nearly all remaining U.S. lawsuits alleging that its talc-based products caused ovarian cancer, marking one of the largest mass-tort settlement efforts in the company's history. The proposed agreement covers approximately 76,000 pending claims and will take effect only if at least 95% of eligible claimants agree to participate.

Sandoz, the global leader in affordable medicines, confirms that the Agência Nacional de Vigilância Sanitária (ANVISA) has granted marketing authorisation for Owozy® (semaglutide), which Sandoz will commercialise in Brazil in partnership with Adalvo.

A new study published in The BMJ has found that adults with type 2 diabetes who use glucagon-like peptide-1 receptor agonists (GLP-1 RAs), including medications such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), may face a higher risk of developing non-scarring hair loss (alopecia) compared with patients taking other commonly prescribed diabetes medicines.